clinical trial · NCT05546866
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Non-small Cell Lung CancerOsimertinib
brief summary
This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.
started
Feb 9, 2023
primary completion
Jun 30, 2029
completion
Jun 30, 2029
last updated
May 13, 2026
official title
An Open-label, Prospective, Multi-center, Single-arm Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in Non-small Cell Lung Cancer (NSCLC) With Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol